<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">107451</article-id>
<article-id pub-id-type="doi">10.7554/eLife.107451</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.107451.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.2</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Cancer Biology</subject>
</subj-group>
</article-categories><title-group>
<article-title>SETD2 suppresses tumorigenesis in a KRAS<sup>G12C</sup>-driven lung cancer model and its catalytic activity is regulated by histone acetylation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1078-9888</contrib-id>
<name>
<surname>Mack</surname>
<given-names>Ricardo J</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">*</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Flores</surname>
<given-names>Natasha M</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="author-notes" rid="n1">*</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5898-0847</contrib-id>
<name>
<surname>Fox</surname>
<given-names>Geoffrey C</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dong</surname>
<given-names>Hanyang</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cebeci</surname>
<given-names>Metehan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hausmann</surname>
<given-names>Simone</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chasan</surname>
<given-names>Tourkian</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dowen</surname>
<given-names>Jill M</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a5">5</xref>
<xref ref-type="aff" rid="a6">6</xref>
<xref ref-type="aff" rid="a7">7</xref>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4947-6259</contrib-id>
<name>
<surname>Strahl</surname>
<given-names>Brian D</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a5">5</xref>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5820-8344</contrib-id>
<name>
<surname>Mazur</surname>
<given-names>Pawel K</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<email>pkmazur@mdanderson.org</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1365-4463</contrib-id>
<name>
<surname>Gozani</surname>
<given-names>Or</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<email>ogozani@stanford.edu</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Department of Biology, Stanford University</institution></institution-wrap>, <city>Stanford</city>, <country country="US">United States</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Cancer Biology Training Program, Stanford University, School of Medicine</institution></institution-wrap>, <city>Stanford</city>, <country country="US">United States</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center</institution></institution-wrap>, <city>Houston</city>, <country country="US">United States</country></aff>
<aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Curriculum in Genetics &amp; Molecular Biology, University of North Carolina at Chapel Hill</institution></institution-wrap>, <city>Chapel Hill</city>, <country country="US">United States</country></aff>
<aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Department of Biochemistry &amp; Biophysics, University of North Carolina at Chapel Hill</institution></institution-wrap>, <city>Chapel Hill</city>, <country country="US">United States</country></aff>
<aff id="a6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Department of Biology, University of North Carolina at Chapel Hill</institution></institution-wrap>, <city>Chapel Hill</city>, <country country="US">United States</country></aff>
<aff id="a7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Integrative Program for Biological and Genome Sciences, University of North Carolina at Chapel Hill</institution></institution-wrap>, <city>Chapel Hill</city>, <country country="US">United States</country></aff>
<aff id="a8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0130frc33</institution-id><institution>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill</institution></institution-wrap>, <city>Chapel Hill</city>, <country country="US">United States</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Shi</surname>
<given-names>Xiaobing</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Van Andel Institute</institution>
</institution-wrap>
<city>Grand Rapids</city>
<country country="US">United States</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Dalal</surname>
<given-names>Yamini</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>National Cancer Institute</institution>
</institution-wrap>
<city>Bethesda</city>
<country country="US">United States</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="equal"><label>*</label><p>Equal contribution</p></fn>
<fn fn-type="coi-statement"><p>Competing interests: O.G. is a co-scientific founder and shareholders of K36 Therapeutics, Inc. and Alternative Bio, Inc. P.K.M. is a consultant and stockholder of Ikena Oncology, Inc. and Alternative bio, Inc. O.G. and B.D.S. are board members, co-scientific founders, and shareholders of EpiCypher, Inc. The other authors declare no competing interests.</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2025-07-09">
<day>09</day>
<month>07</month>
<year>2025</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2025-08-29">
<day>29</day>
<month>08</month>
<year>2025</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP107451</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2025-05-16">
<day>16</day>
<month>05</month>
<year>2025</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2025-05-18">
<day>18</day>
<month>05</month>
<year>2025</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.05.16.654513"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2025-07-09">
<day>09</day>
<month>07</month>
<year>2025</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.107451.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.107451.1.sa2">eLife Assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.107451.1.sa1">Reviewer #1 (Public review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.107451.1.sa0">Reviewer #2 (Public review):</self-uri>
<self-uri content-type="author-comment" xlink:href="https://doi.org/10.7554/eLife.107451.1.sa3">Author response:</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2025, Mack et al</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Mack et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-107451-v2.pdf"/>
<abstract>
<title>Abstract</title><p>Histone H3 trimethylation at lysine 36 (H3K36me3) is a key chromatin modification that regulates fundamental physiologic and pathologic processes. In humans, SETD2 is the only known enzyme that catalyzes H3K36me3 in somatic cells and is implicated in tumor suppression across multiple cancer types. While there is considerable crosstalk between the SETD2-H3K36me3 axis and other epigenetic modifications, much remains to be understood. Here, we show that SETD2 functions as a potent tumor suppressor in a KRAS<sup>G12C</sup>-driven lung adenocarcinoma (LUAD) mouse model, and that acetylation enhances SETD2 <italic>in vitro</italic> methylation of H3K36 on nucleosome substrates. <italic>In vivo</italic>, <italic>SETD2</italic> ablation accelerates lethality in an autochthonous KRAS<sup>G12C</sup>-driven LUAD mouse tumor model. Biochemical analyses reveal that polyacetylation of histone tails in a nucleosome context promote H3K36 methylation by SETD2. In addition, monoacetylation exerts position-specific effects to stimulate SETD2 methylation activity. In contrast, mono-ubiquitination at various histone sites, including at H2AK119 and H2BK120, does not affect SETD2 methylation of nucleosomes. Together, these findings provide insight into how SETD2 integrates histone modification signals to regulate H3K36 methylation and highlights the potential role of SETD2-associated epigenetic crosstalk in cancer pathogenesis.</p>
</abstract>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Revisions added to address comments from Reviewers at eLife.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Protein lysine methylation is a common post-translational modification (PTM) that occurs in three distinct states—monomethylation (Kme1), dimethylation (Kme2), and trimethylation (Kme3)—depending on whether one, two or three methyl groups are added to the lysine sidechain (<xref ref-type="bibr" rid="c1">1</xref>). Lysine methylation is catalyzed by a class of enzymes named protein <underline>lysine m</underline>ethyltransferases (KMTs) and removed by protein lysine demethylases (<xref ref-type="bibr" rid="c1">1</xref>). Methylation at H3K36 is an evolutionarily conserved histone modification (<xref ref-type="bibr" rid="c2">2</xref>). In humans, mutations in the enzymes that determine H3K36 methylation dynamics are linked to a variety of developmental disorders and cancer (<xref ref-type="bibr" rid="c2">2</xref>–<xref ref-type="bibr" rid="c4">4</xref>). The state and extent of methylation at H3K36 is synthesized by distinct KMTs, with H3K36me2 generated by four related enzymes (NSD1, NSD2, NSD3, and ASH1L), whereas SETD2 is the only human enzyme in somatic cells that has been reproducibly shown to generate H3K36me3 (<xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c3">3</xref>, <xref ref-type="bibr" rid="c5">5</xref>). SETD2 and its cognate mark H3K36me3 generally occupy transcriptionally active regions. Functionally, SETD2 influences core molecular processes such as DNA methylation, RNA processing, DNA repair, and genomic integrity (<xref ref-type="bibr" rid="c6">6</xref>–<xref ref-type="bibr" rid="c11">11</xref>). Notably, while H3K36me2-generating enzymes like NSD2 and NSD3 promote oncogenesis when mutated or overexpressed (e.g. (<xref ref-type="bibr" rid="c12">12</xref>–<xref ref-type="bibr" rid="c17">17</xref>)), SETD2 is a potent tumor suppressor frequently mutated in clear cell renal cell carcinoma (ccRCC) (<xref ref-type="bibr" rid="c9">9</xref>, <xref ref-type="bibr" rid="c18">18</xref>) and several other cancers. For example, the <italic>SETD2</italic> gene (along with other important tumor suppressors) is located within chromosome 3p, a genomic region that is reported to show loss of heterozygosity in ∼90-95% of ccRCC tumors (<xref ref-type="bibr" rid="c19">19</xref>). In ccRCC pathogenesis, ∼10-20% of tumors acquire SETD2 mutation on the second intact allele (or more rarely acquire mutations on both alleles) resulting in biallelic loss of <italic>SETD2</italic> and H3K36me3 depletion (<xref ref-type="bibr" rid="c9">9</xref>, <xref ref-type="bibr" rid="c18">18</xref>, <xref ref-type="bibr" rid="c19">19</xref>). Deletions and/or loss-of-function mutations in SETD2 are also detected recurrently in different types of leukemia and solid tumors including gastroesophageal cancers and lung adenocarcinoma (LUAD), though at lower frequency than seen in ccRCC (<xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c20">20</xref>–<xref ref-type="bibr" rid="c23">23</xref>).</p>
<p>SETD2 is a large protein with multiple functional regions and domains beyond its ability to catalyze H3K36me3. Thus, the precise role of H3K36me3 in SETD2-associated functions remain unclear. One established function of SETD2-catalyzed H3K36me3 is to allosterically inhibit the ability of the PRC2 complex to synthesize the repressive H3K27me3 chromatin modification (<xref ref-type="bibr" rid="c24">24</xref>–<xref ref-type="bibr" rid="c29">29</xref>). Further, H3K36me3, via its recognition by the PWWP domain of DNMT3b, promotes targeted DNA methylation (<xref ref-type="bibr" rid="c6">6</xref>). However, beyond H3K27me3 and DNA methylation, potential crosstalk between other epigenetic modifications and SETD2-mediated catalysis of H3K36me3 in the regulation of SETD2 function are relatively unexplored. Here, we test the <italic>in vivo</italic> role of SETD2 in suppressing KRAS<sup>G12C</sup>-driven tumorigenesis in LUAD, as G12C is the most common KRAS mutation in this tumor type, and identify potential regulatory roles for histone acetylation, particularly H3K27 acetylation, in promoting <italic>in vitro</italic> methylation of nucleosomes by SETD2.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>SETD2 deletion accelerates KRAS<sup>G12C</sup>-driven lung cancer pathogenesis in vivo</title>
<p>Several elegant previous <italic>in vivo</italic> studies utilizing either CRISPR-based or gene knockout approaches demonstrated that loss of SETD2 promotes lung adenocarcinoma (LUAD) tumorigenesis in the canonical KRAS<sup>G12D</sup>-driven LUAD mouse tumor model (<xref ref-type="bibr" rid="c22">22</xref>, <xref ref-type="bibr" rid="c30">30</xref>–<xref ref-type="bibr" rid="c33">33</xref>). As G12C is the most common KRAS oncogenic variant in LUAD (<xref ref-type="bibr" rid="c34">34</xref>, <xref ref-type="bibr" rid="c35">35</xref>), we used a recently developed KRAS<sup>G12C</sup>-driven LUAD mouse model (named <italic>K<sup>c</sup>P</italic>) (<xref ref-type="bibr" rid="c36">36</xref>) to test whether the additional loss of SETD2 (named <italic>K<sup>c</sup>P;Setd2</italic>) impacted cancer pathogenesis <italic>in vivo</italic> like it does in a G12D oncogenic mutant background (<xref rid="fig1" ref-type="fig">Figs. 1A-C</xref>). In this model, expression of the <italic>Kras<sup>G12C</sup></italic> mutant allele and homozygous deletions of <italic>p53</italic> and <italic>Setd2</italic> are induced by intratracheal lavage of adenovirus expressing Cre recombinase (Ad-Cre) (<xref ref-type="bibr" rid="c36">36</xref>). Following viral infection, <italic>K<sup>c</sup>P</italic> mutant mice develop widespread LUAD with 100% penetrance (see schematic, <xref rid="fig1" ref-type="fig">Fig. 1D</xref>; (<xref ref-type="bibr" rid="c36">36</xref>)). Consistent with the principal catalytic activity of SETD2 being generation of H3K36me3, <italic>SETD2</italic> deletion resulted in loss of H3K36me3 immuno<underline>h</underline>isto<underline>c</underline>hemistry (IHC) signal comparing LUAD tissue sections from <italic>K<sup>c</sup>P</italic> and <italic>K<sup>c</sup>P;Setd2</italic> mice (<xref rid="fig1" ref-type="fig">Fig. 1E</xref>). Moreover, <italic>SETD2</italic> depletion accelerated tumorigenesis as measured by a modest increase in tumor nodule numbers and a four-fold increase in tumor burden (<xref rid="fig1" ref-type="fig">Figs. 1F-G</xref>). Loss of SETD2 also caused an increase in cellular proliferation in tumors, but did not significantly impact apoptosis levels (<xref rid="fig1" ref-type="fig">Figs. 1E</xref>, H-I). Finally, SETD2 depletion resulted in a 40% decline in animal overall median survival time (<xref rid="fig1" ref-type="fig">Fig. 1J</xref>). Thus, as previously observed with oncogenic KRAS<sup>G12D</sup>-based models (<xref ref-type="bibr" rid="c22">22</xref>, <xref ref-type="bibr" rid="c30">30</xref>–<xref ref-type="bibr" rid="c33">33</xref>), SETD2 loss accelerates mutant KRAS<sup>G12C</sup>-driven malignancy <italic>in vivo</italic>.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Fig 1.</label>
<caption><title>SETD2 ablation promotes KRAS<sup>G12C</sup>-driven lung tumorigenesis in vivo.</title>
<p><bold>A,</bold> Schematic of the <italic>Setd2<sup>LoxP/LoxP</sup></italic>conditional allele. In the presence of Cre recombinase, exon 3 is deleted to disrupt <italic>Setd2</italic> expression. <bold>B,</bold> Confirmation of <italic>Setd2<sup>LoxP/LoxP</sup></italic> conditional allele by PCR on DNA isolated from mouse tail biopsies from indicated mouse genotypes, expected product sizes are marked. C, Schematic of generation of LUAD model driven by Cre-recombinase inducible conditional oncogenic <italic>Kras<sup>G12C</sup></italic> mutation and deletion of p53 (<italic>K<sup>C</sup>P</italic>) and <italic>Setd2</italic> (<italic>K<sup>C</sup>P;Setd2</italic>). <bold>D,</bold> Experimental design to assess effects of SETD2 ablation on LUAD pathogenesis in <italic>K<sup>C</sup>P</italic> model. <bold>E,</bold> Representative HE and IHC staining with indicated antibodies of lung tumors from <italic>K<sup>C</sup>P</italic> and <italic>K<sup>C</sup>P;Setd2</italic> mutant mice at 10 weeks after Ad-Cre induction (n=6/group). H3K36me3 serves as a proxy of SETD2 ablation in tumor cells in <italic>K<sup>C</sup>P;Setd2</italic> mutant mice. P values determined by two-tailed unpaired t-test; boxes: 25th to 75th percentile, whiskers: min. to max., center line: median; scale bars: 100 µm. <bold>F-I,</bold> Quantification of tumor number, tumor burden, proliferation (Ki67+) and cell death (cleaved Caspase3+) in <italic>K<sup>C</sup>P</italic> and <italic>K<sup>C</sup>P;Setd2</italic> samples as in e. <bold>J,</bold> Kaplan-Meier survival curves of <italic>K<sup>C</sup>P</italic> control (n=8, median survival 151 days) and <italic>K<sup>C</sup>P;Setd2</italic> mutant mice (n=8, median survival 92 days) mutant mice. <italic>P</italic> values determined by the log-rank test.</p></caption>
<graphic xlink:href="654513v2_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2b">
<title>SETD2 in vitro methylation activity on H3K36 methylated nucleosomes</title>
<p>In humans, SETD2 is the only enzyme in somatic cells that generates the canonical epigenetic modification H3K36me3 (<xref ref-type="bibr" rid="c5">5</xref>). In contrast, four KMTs (NSD1, NSD2, NSD3, and ASH1L) generate H3K36me2 (<xref ref-type="bibr" rid="c3">3</xref>). Notably, while SETD2 is tumor suppressive (e.g. see <xref rid="fig1" ref-type="fig">Fig. 1</xref>), the H3K36me2 KMTs are generally oncogenic (<xref ref-type="bibr" rid="c3">3</xref>). While the specific role of SETD2-catalyzed H3K36me3 in cancer pathogenesis remains unclear, it is intriguing that the di-methyl and tri-methyl states at H3K36 may have profoundly different impacts on tumorigenesis. In this regard, it has been postulated that SETD2 requires pre-existing H3K36me2 to generate the tri-methyl state at K36 (<xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c3">3</xref>). However, previous work demonstrated that the isolated catalytic SET domain of SETD2 methylates unmodified <underline>r</underline>ecombinant <underline>Nuc</underline>leosome<underline>s</underline> (rNucs) <italic>in vitro</italic> with the same efficiency as methyl-lysine analog (MLA)-based H3K<sub>C</sub>36me2 rNucs (<xref ref-type="bibr" rid="c37">37</xref>). While MLA chemistry is generally able to faithfully model native methyl-lysine function (e.g., recognition by reader domains), there are examples where the sulfur moiety compromises functionality (<xref ref-type="bibr" rid="c38">38</xref>). Thus, we tested the impact of native methylation installed at H3K36 on the enzymatic activity of the catalytic region of SETD2 that encompasses the SET domain as well as the pre- and post-SET regions (hereafter named SETD2<sub>SET</sub>; <xref rid="fig2" ref-type="fig">Fig. 2A</xref>).</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Fig 2.</label>
<caption><title>SETD2 methylates unmodified, H3K36me1-, and H3K36me2-modified nucleosomes, but not those bearing H3K36me3</title>
<p><bold>A,</bold> Schematic of SETD2 domain structure, with the catalytic region used in the biochemical assays (SETD2<sub>SET</sub>) indicated. <bold>B,</bold> SETD2<sub>SET</sub> <italic>in vitro</italic> methylation reactions with radiolabeled <sup>3</sup>H-SAM on unmodified (H3), H3K36me1, H3K36me2, or H3K36me3 recombinant nucleosomes (rNuc) substrates as indicated. K36me: methylated H3K36. Top, autoradiography; bottom, Coomassie blue staining. <bold>C,</bold> Methylation (MTase-Glo) assays (see methods) with enzyme and substrates as in (B). SAH concentration serves as a measurement of methylation. Activity is normalized to control conditions. Data are means ± SEM from 3 independent replicates. <italic>P</italic> values determined by one-way ANOVA. <bold>D,</bold> Methylation reactions as in (B) using NSD2<sub>SET</sub> as the enzyme and the indicated rNucs as substrates. Top, autoradiography; bottom, Coomassie blue staining. <bold>E,</bold> Western blot analysis with the indicated antibodies on the indicated rNucs as in (B). <bold>F,</bold> SETD2<sub>SET</sub> methylation assays as in (B) using non-radiolabeled SAM and methylation detected by Western analyses using the antibodies characterized in (E). H3 is shown as a loading control.</p></caption>
<graphic xlink:href="654513v2_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p><italic>In vitro</italic> methylation assays were performed using recombinant SETD2<sub>SET</sub>, radiolabeled <italic>S</italic>- Adenosyl-methionine (SAM) as the methyl donor, and rNucs that were either unmethylated or harboring me1, me2, or me3 at K36 as substrate. The SETD2<sub>SET</sub> domain methylated all the rNuc substrates besides the tri-methylated sample (<xref rid="fig2" ref-type="fig">Fig. 2B</xref>). Specifically, the highest signal was observed using unmodified rNucs, with the intensity of the signal decreasing sequentially on H3K36me1 and H3K36me2 rNuc substrates, likely reflecting the reduced capacity of these H3K36 methylated histones to be further methylated (<xref rid="fig2" ref-type="fig">Fig. 2B</xref>). SETD2<sub>SET</sub> showed no detectable methylation activity on H3K36me3 rNucs, consistent with K36 being 100% saturated with methylation and thus there being no more sites available to be methylated and the specificity of SETD2 for K36 versus other lysine residues on histones (<xref rid="fig2" ref-type="fig">Fig. 2B</xref>). Similar results were observed using an independent quantitative method that measures production of <italic>S</italic>-Adenosyl-homocysteine (SAH) – a key byproduct of the methylation reaction (<xref rid="fig2" ref-type="fig">Fig. 2C</xref>). Like with SETD2<sub>SET</sub>, the NSD2<sub>SET</sub> domain showed the strongest methylation activity on unmodified rNucs compared to H3K36me1 rNucs, and NSD2<sub>SET</sub> has no activity on H3K36me2/3 rNucs, consistent with NSD2 being a selective H3K36me2-KMT (<xref rid="fig2" ref-type="fig">Fig. 2D</xref>).</p>
<p>To gain insight into the efficiency of conversion between methyl states at K36 for SETD2, we identified methyl-state specific H3K36 antibodies for the three methyl states (<xref rid="fig2" ref-type="fig">Fig. 2E</xref>). We next tested how lysine methyl-state transition on the various H3K36 methylated nucleosome substrates impact SETD2<sub>SET</sub> activity. To this end, we performed methylation assays with SETD2<sub>SET</sub> using non-radiolabeled SAM and detected modification of rNucs using the H3K36me state-specific antibodies (<xref rid="fig2" ref-type="fig">Fig. 2E</xref>). Under our reaction conditions (see Methods), SETD2<sub>SET</sub> generated all three methyl states (me1, me2, and me3) when using unmodified rNucs as substrate (<xref rid="fig2" ref-type="fig">Fig. 2F</xref>). On H3K36me1-rNucs, SETD2<sub>SET</sub> generated both higher states of methylation at K36 (H3K36me2 and H3K36me3), whereas H3K36me2-rNucs were naturally only converted to the trimethyl state (<xref rid="fig2" ref-type="fig">Fig. 2F</xref>). The conversion to the trimethyl state at K36 was most efficient on H3K36me2-rNucs, which likely reflects the reaction having poor <italic>in vitro</italic> processivity (<xref rid="fig2" ref-type="fig">Fig. 2F</xref>). These results indicate that the ability of SETD2<sub>SET</sub> to generate H3K36me3 <italic>in vitro</italic> does not require pre-existing methylation, consistent with previous studies (<xref ref-type="bibr" rid="c37">37</xref>). The data further suggests that, at least <italic>in vitro</italic>, SETD2<sub>SET</sub> is agnostic about the state of methylation at H3K36 on nucleosome substrates.</p>
</sec>
<sec id="s2c">
<title>Specific histone acetylation events enhance SETD2 methylation activity</title>
<p>Histone acetylation promotes transcription and other DNA-templated processes through several mechanisms, such as the recognition of acetyl-lysine by reader proteins and the neutralization of DNA-histone interactions (<xref ref-type="bibr" rid="c39">39</xref>–<xref ref-type="bibr" rid="c41">41</xref>). The combined consequences of such activities decondense chromatin to increase accessibility to the underlying DNA. In addition, neutralizing the positive charge on the lysine side chain facilitates accessibility of KMTs to the unstructured histone tails by disrupting tail-DNA interactions, as was previously shown for the MLL1 KMT complex (<xref ref-type="bibr" rid="c40">40</xref>–<xref ref-type="bibr" rid="c43">43</xref>). Given the relatively restrictive location of K36 of H3 near the globular domain of the nucleosome, we speculated that histone acetylation might render the residue more accessible to methylation by SETD2. To test this idea, methylation assays with SETD2<sub>SET</sub> were performed using substrates that were either unmodified rNucs or rNucs with tetra-acetylated lysine residues on the N-terminus tails of H2A, H3, or H4 (see schematic, <xref rid="fig3" ref-type="fig">Fig. 3A</xref>). SETD2<sub>SET</sub> methylation activity as determined by incorporation of radiolabeled SAM or SAH production was enhanced on tetra-acetylated rNucs compared to control rNucs irrespective of the acetylated histone tail (<xref rid="fig3" ref-type="fig">Figs. 3B-C</xref>). A similar trend was observed in methylation assays using the NSD2<sub>SET</sub> domain, though H3 tetra-acetylation seemed to have the biggest impact compared to acetylation of H2A and H4 (<xref rid="fig3" ref-type="fig">Fig. 3D</xref>). In contrast, methylation assays using hDOT1L, the KMT responsible for H3K79 methylation – a PTM situated in the nucleosome globular domain – was not enhanced by acetylation of the various histone tails (<xref rid="fig3" ref-type="fig">Fig. 3E</xref>). Collectively, these data suggest that a high degree of acetylation may increase the accessibility of H3K36 to the enzymes that methylate this residue.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Fig 3.</label>
<caption><title>Histone poly-acetylation enhances SETD2<sub>SET</sub> activity</title>
<p><bold>A,</bold> Schematic showing the tetra-acetylated rNuc tested in the study. <bold>B,</bold> <italic>In vitro</italic> methylation reactions with SETD2<sub>SET</sub> as in <xref rid="fig2" ref-type="fig">Fig. 2B</xref> using the indicated tetra-acetylated rNucs. Top, autoradiography; bottom, Coomassie blue staining. <bold>C,</bold> MTase-Glo assays as in <xref rid="fig2" ref-type="fig">Fig. 2C</xref> using the indicated tetra-acetylated rNucs. Data are means ± SEM from 12 independent replicates. <italic>P</italic> values determined by one-way ANOVA. <bold>D,</bold> Methylation reactions as in (B) using NSD2<sub>SET</sub> as enzyme. Top, autoradiography; bottom, Coomassie blue staining. <bold>E,</bold> Methylation reactions as in (B) using DOT1L as enzyme. Top, autoradiography; bottom, Coomassie blue staining.</p></caption>
<graphic xlink:href="654513v2_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>We next explored whether acetylation of individual residues on the H3 tail could facilitate SETD2 activity, and if so, whether such an effect depends on the specific acetylation site. To this end, methylation assays with SETD2<sub>SET</sub> were performed using substrates that were either unmodified rNucs or rNucs mono-acetylated at K4, K9, K14, K18, K23, or K27 on the N-terminal tail of H3 (see schematic, <xref rid="fig4" ref-type="fig">Fig. 4A</xref>). Methylation activity, determined by incorporation of radiolabeled SAM (<xref rid="fig4" ref-type="fig">Fig. 4B</xref>) or SAH production (<xref rid="fig4" ref-type="fig">Fig. 4C</xref>), indicated that three different single acetylation sites (K14, K23, and K27) enhanced SETD2<sub>SET</sub> methylation activity on nucleosomes, with the impact likely H3K27ac&gt;H3K14ac&gt;H3K23ac (<xref rid="fig4" ref-type="fig">Figs. 4B-C</xref>). While understanding the molecular basis for the acetylation-mediated enhancement in SETD2 activity will likely require structural investigation, we reasoned that given the proximity and relationship between H3K27 and H3K36 (<xref ref-type="bibr" rid="c24">24</xref>, <xref ref-type="bibr" rid="c44">44</xref>), that acetylation at K27 might impact the interaction between SETD2<sub>SET</sub> and nucleosomes. Consistent with this, SETD2<sub>SET</sub> was subtly more efficiently pulled down when using H3K27ac rNucs as bait compared to unmodified rNucs and the ability of SETD2<sub>SET</sub> to form a complex with recombinant mono-nucleosomes was subtly enhanced in the presence of K27 acetylation (<xref rid="fig4" ref-type="fig">Figs. 4D-E</xref>). These data suggest K27ac may directly or indirectly minorly influence the interaction between SETD2<sub>SET</sub> and its substrate site in the context of nucleosomes (see Discussion).</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Fig 4.</label>
<caption><title>H3K27 acetylation enhances SETD2<sub>SET</sub> binding and activity</title>
<p><bold>A,</bold> Schematic showing the different histone H3 acetylated rNuc tested in the study. <bold>B,</bold> <italic>In vitro</italic> methylation reactions with SETD2<sub>SET</sub> as in <xref rid="fig2" ref-type="fig">Fig. 2B</xref> using the indicated acetylated rNucs. Top, autoradiography; bottom, Coomassie blue staining. <bold>C,</bold> MTase-Glo assays as in <xref rid="fig2" ref-type="fig">Fig. 2C</xref> using the indicated acetylated rNucs. Data are means ± SEM from 6 independent replicates. <italic>P</italic> values determined by one-way ANOVA. <bold>D,</bold> Nucleosome pulldown assay using biotinylated unmodified or H3K27ac nucleosomes as bait to assess binding to GST-SETD2<sub>SET</sub>. Bound protein was detected by Western blotting with indicated antibodies. <bold>E,</bold> Electrophoretic mobility shift assay (EMSA) with increasing concentrations of SETD2<sub>SET</sub> (0–5 μM) incubated with the indicated rNuc (250 nM) and SETD2<sub>SET</sub> binding to rNuc detected by staining DNA with Sybr Gold.</p></caption>
<graphic xlink:href="654513v2_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2d">
<title>Histone ubiquitination does not impact SETD2 methylation activity in vitro</title>
<p>We next investigated how ubiquitination at various histone residues influences SETD2 activity. While methylation at H3K36 directly blocks a key allosteric interaction between the PRC2 complex and unmodified H3K36, H3K27me3 indirectly inhibits H3K36 KMTs. Specifically, H3K27me3 recruits the PRC1 complex, which catalyzes the ubiquitination of H2AK119 (H2AK119ub) (<xref ref-type="bibr" rid="c45">45</xref>). Nucleosomes harboring H2AK119ub antagonize H3K36 enzymes like NSD2 by structurally preventing their proper association with the nucleosome (<xref ref-type="bibr" rid="c44">44</xref>). However, whether H2AK119ub and/or other histone ubiquitination sites impact SETD2 activity is unclear, although studies in yeast have shown the SETD2 homolog, Set2, is influenced by H2BK120ub (<xref ref-type="bibr" rid="c46">46</xref>). Thus, we tested SETD2<sub>SET</sub> activity against a library of ubiquitinated nucleosomes as substrates (see schematic, <xref rid="fig5" ref-type="fig">Fig. 5A</xref>). Surprisingly, assaying methylation by three different methods (utilizing radiolabeled SAM, detecting the different methylation states by Western, and measuring SAH generation), histone ubiquitination did not impact SETD2 activity (<xref rid="fig5" ref-type="fig">Fig. 5B-D</xref>; note that the H3K36me2 antibody is blocked by H3K14 and H3K18 ubiquitination). In contrast, as expected, H2AK119ub specifically reduced NSD2 activity (<xref rid="fig5" ref-type="fig">Fig. 5E</xref>). Collectively, these findings indicate that the isolated catalytic domain of SETD2, unlike for NSD2, is not influenced by histone ubiquitination, suggesting potential functional differences in how H3K36 enzymes interact with the ubiquitinated nucleosome landscape.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Fig 5.</label>
<caption><title>Histone ubiquitination does not affect SETD2<sub>SET</sub> activity</title>
<p><bold>A,</bold> Schematic showing the different histone ubiquitinated rNuc tested in the study. <bold>B,</bold> <italic>In vitro</italic> methylation reactions with SETD2<sub>SET</sub> as in <xref rid="fig2" ref-type="fig">Figure 2B</xref> using the indicated ubiquitinated rNucs. Top, autoradiography; bottom, Coomassie blue staining. <bold>C,</bold> SETD2<sub>SET</sub> methylation assays as in <xref rid="fig2" ref-type="fig">Fig. 2F</xref> using non-radiolabeled SAM and methylation detected by Western analysis using the indicated antibodies. H3 is shown as a loading control. Note that H3K14ub and H3K18ub interfere with the αH3K36me2 antibody from recognizing H3K36me2. <bold>D,</bold> MTase-Glo assays as in <xref rid="fig2" ref-type="fig">Fig. 2C</xref> using the indicated rNucs. Data are means ± SEM from 6 independent replicates. <italic>P</italic> values determined by one-way ANOVA. <bold>E,</bold> Methylation reactions as in (B) using NSD2<sub>SET</sub> as enzyme. Top, autoradiography; bottom, Coomassie blue staining.</p></caption>
<graphic xlink:href="654513v2_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>SETD2, via catalytic and non-catalytic mechanisms, regulates fundamental nuclear processes. Mutations in SETD2 cause Sotos-like syndrome, an overgrowth disorder, and loss of SETD2 commonly occurs and is thought to be tumor suppressive in ccRCC and many other malignancies (<xref ref-type="bibr" rid="c3">3</xref>, <xref ref-type="bibr" rid="c47">47</xref>). Indeed, SETD2 was identified as one of the most mutated genes in a saturation analysis of 21 cancer types (<xref ref-type="bibr" rid="c48">48</xref>). Consistent with these observations and previous lung cancer mouse modeling studies (<xref ref-type="bibr" rid="c22">22</xref>, <xref ref-type="bibr" rid="c32">32</xref>, <xref ref-type="bibr" rid="c33">33</xref>), we find that SETD2 ablation strongly accelerates LUAD malignant progression and lethality in a KRAS<sup>G12C</sup>-driven mouse tumor model (see <xref rid="fig1" ref-type="fig">Fig. 1</xref>). While these studies demonstrate that CRISPR-mediated endogenous depletion of SETD2 or homozygous genetic deletion of <italic>SETD2</italic> promote tumorigenesis, future work will help elucidate the specific contributions of H3K36me3 synthesis and other SETD2 functional domains in tumor suppression. In this context, EZM0414, a clinical-grade SETD2 inhibitor, was being evaluated in a Phase I clinical trial as a therapeutic in relapsed or refractory multiple myeloma and diffuse large B cell lymphoma, suggesting that at least in these cancer types, H3K36me3 generation may be oncogenic (NCT05121103; note this trial was terminated). Whether SETD2-mediated catalysis of H3K36me3 is tumor suppressive or oncogenic in a tumor context-dependent manner—and how this activity relates to SETD2’s other functions—are potentially important questions for future investigation.</p>
<p>Consistent with previous work, our biochemical analyses using native designer nucleosomes indicates that—at least in isolation—the catalytic domain of SETD2 does not exhibit a preference for substrates bearing mono- or di-methylation at K36 compared to the unmodified state (see <xref rid="fig2" ref-type="fig">Fig. 2</xref>) (<xref ref-type="bibr" rid="c37">37</xref>). We speculate that physiologically SETD2 uses all three lower states of methylation at H3K36me (me0-me2) to generate endogenous H3K36me3, with the specific precursor state determined by the underlying biology and genomic context. Our analyses also uncovered an unanticipated regulatory role for histone acetylation in activating SETD2 <italic>in vitro</italic> methylation activity on nucleosomes. Why some acetylation sites increased SETD2 activity whereas others did not is presently unclear. One possibility is that certain acetylation events, for example H3K27ac, may alter histone-DNA interactions in a manner that renders H3K36 more accessible to the catalytic pocket of SETD2. Additionally, our data suggests that SETD2 may interact more strongly with H3K27ac nucleosomes compared to unmodified nucleosomes, which would promote higher levels of methylation (<xref rid="fig4" ref-type="fig">Fig. 4</xref>). Finally, we observed a divergence between SETD2 and H3K36me2-KMTs such as NSD2, in that SETD2 is neither inhibited by H2AK119ub nor regulated by H2BK120ub (<xref rid="fig5" ref-type="fig">Fig. 5</xref>). These data are consistent with recent cryo-EM-based structural studies, which provide a molecular rationale for why NSD2, but not SETD2, would be impacted by a large modification within the C-terminal region of H2A (<xref ref-type="bibr" rid="c44">44</xref>, <xref ref-type="bibr" rid="c49">49</xref>, <xref ref-type="bibr" rid="c50">50</xref>). Future functional and epigenomic studies will be crucial for understanding how epigenetic modifications such as acetylation and ubiquitination regulate SETD2 activity in physiological and pathological settings.</p>
</sec>
<sec id="s4">
<title>Materials &amp; methods</title>
<sec id="s4a">
<title>Protein expression and purification</title>
<p>The SETD2<sub>SET</sub> (aa1418-1714, NCBI Sequence: NC_000003.12), NSD2<sub>SET</sub> (aa959-1365, NCBI Sequence: NC_000004.12), and DOT1L (aa1-416, NCBI Sequence: NC_000019.10) were cloned into pGEX-6P-1 separately. <italic>Escherichia coli</italic> Rossetta cells were transformed with the respective expression vectors and cultured in LB medium (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl) supplemented with 0.1 mM IPTG (isopropyl 1-thio-ϕ3-D-galactopyranoside, Sigma) at 18 °C for 16–20 h. Cells were lysed using sonicator, lysates were cleared by centrifugation at 12,000 rpm for 20 min and the supernatants were incubated with Glutathione Sepharose (GE Healthcare #17-0756-01); bound proteins were washed and eluted in 10 mM reduced glutathione (Sigma #G4251-25G). Protein concentrations were measured using Pierce Coomassie Plus Assay (Thermo #23236).</p>
<p>For expression and purification of GST-SETD2 (1345–1711) used in <xref rid="fig4" ref-type="fig">Figure 4D</xref>, BL21.DE3(pLysS) E. coli transformed with a recombinant expression plasmid encoding GST-tagged human SETD2 catalytic domain (residues 1345-1711) was grown in LB supplemented with 50 µg/mL carbenicillin at 37° C until OD600 reached ∼0.6. Cultures were then transferred to 16° C and induced with 1 mM IPTG (Sigma) overnight and harvested by centrifugation, flash frozen in liquid nitrogen, and stored at −20° C until use. Thawed cell pellets were resuspended in lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT, 1 mM PMSF) supplemented with 250 U of Pierce Universal Nuclease (ThermoFisher) and 1 mg/mL lysozyme (Sigma) and incubated at 37° C for 10 minutes. Cells were then lysed by sonication (5 x 30 seconds, 40% cycle, 40% power) and lysates clarified by centrifugation before application to glutathione agarose beads (Pierce) pre-equilibrated in wash buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT, 1 mM PMSF). Following three sequential washes with wash buffer, proteins were eluted in ∼1 mL fractions with wash buffer supplemented with 10 mM glutathione. Fractions containing purified GST-SETD2 were pooled, concentrated by centrifugation filtration (EMD Millipore, MWCO 30 kDa). Glycerol was added to 20% final concentration, aliquoted, and stored at −80°C until use (<xref ref-type="bibr" rid="c51">51</xref>).</p>
</sec>
<sec id="s4b">
<title>In vitro methylation reactions</title>
<p>The methylation reactions on nucleosomes were performed similar as previously described (<xref ref-type="bibr" rid="c52">52</xref>). Briefly, 350 nM recombinant enzymes were mixed with 500 nM mononucleosome (EpiCypher, H3-unmodified #16-0006, H3K36me1 #16-0322, H3K36me2 #16-0319, H3K36me3#16-0390, H2A-4xac#16-0376, H3-4xac#16-0336, H4-4xac#16-0313, H3K4ac#16-0342, H3K9ac#16-0314, H3K14ac#16-0343, H3K18ac#16-0372, H3K23ac#16-0364, H3K27ac#16-0365, H2AK15ub#16-0399, H2BK119ub#16-0395, H2AK120ub#16-0396, H3K14ub#16-0398, H3K18ub#16-0401) in reaction buffer (containing 250 mM Tris pH 8.0, 100 mM KCl, 25 mM MgCl<sub>2</sub> and 50% glycerol), after adding 20 µM SAM (S-adenosylmethionine), the mixture was incubated at 30°C for 3 hours.</p>
</sec>
<sec id="s4c">
<title>MTase-Glo methyltransferase assay</title>
<p>The MTase-Glo methyltransferase assay kit (Promega #V7602) was used to measure enzymatic activity in the presence of different substrates. Specifically, we established an assay in 10 μL reaction mix containing 35 nM of KMT enzyme, 4 µM SAM, 50 nM mononucleosomes (EpiCypher), and MTase-Glo reagent (1×) in reaction buffer (containing 250 mM Tris pH 8.0, 100 mM KCl, 25 mM MgCl2 and 50% glycerol) arrayed in a white 384-well microplate (Corning #CLS3574). Each independent biochemical reaction was performed in triplicate and incubated for 3 hours at 30°C. Subsequently, 10 μL of MTase-Glo detection solution was added and incubated for 1 hour at room temperature. Reactions were detected by luminescence.</p>
</sec>
<sec id="s4d">
<title>Western blot analyses</title>
<p>For western blot analysis, protein samples were resolved by SDS–PAGE and transferred to a PVDF membrane. The following antibodies were used (at the indicated dilutions): H3K36me1 (Abclonal #A11141, 1:1000), H3K36me2 (ThermoFisher #701767, 1:1000), H3K36me3 (EpiCypher #13-0058, 1:1,000), H3 (EpiCypher #13-0001, 1:10000).</p>
</sec>
<sec id="s4e">
<title>Animal models</title>
<p><italic>Kras<sup>cKI-G12C</sup></italic> and <italic>Trp53<sup>loxP/loxP</sup></italic> mutant mice have been described before (<xref ref-type="bibr" rid="c36">36</xref>, <xref ref-type="bibr" rid="c53">53</xref>). Conditional <italic>Setd2<sup>loxP/loxP</sup></italic> mouse strain was obtained from Shanghai Model Organisms Center, Inc (Cat. NO. NM-CKO-190069). Briefly, the Setd2<italic><sup>loxP/loxP</sup></italic>targeted knockin sequence includes the Neo-LacZ cassette flanked by Frt sites and exon 3 sequence flanked by LoxP sites. Founder mice were crossed with Rosa26-FlpO deleter strain (<xref ref-type="bibr" rid="c54">54</xref>) to generate <italic>Setd2<sup>loxP/loxP</sup></italic>conditional allele. Confirmation of <italic>Setd2<sup>loxP/loxP</sup></italic> conditional allele targeting was performed by PCR on DNA isolated from mouse tail biopsies and the following primers: Forward: AGCTGACCTGATTTCTCCTTTAG; Reverse: AACAGCTGAGAGTGACCATGAG. Mice were maintained on a mixed C57BL/6;FVB strain background and we systematically used littermates as controls in all the experiments. Both male and female animals were used in the experiments, and no sex differences were noted. In all experiments, animals were numbered, and experiments were conducted in a blinded fashion. After data collection, genotypes were revealed, and animals were assigned to groups for analysis. None of the mice with the appropriate genotype were excluded from this study or used in any other experiments. All mice were co-housed with littermates (2–5 per cage) in pathogen-free facility with standard controlled temperature of 72 °F, with a humidity of 30–70%, and a light cycle of 12 h on/12 h off set from 7am to 7pm and with unrestricted access to standard food and water under the supervision of veterinarians, in an AALAC-accredited animal facility at the University of Texas M.D. Anderson Cancer Center (MDACC). Mouse handling and care followed the NIH Guide for Care and Use of Laboratory Animals. All animal procedures followed the guidelines of and were approved by the MDACC Institutional Animal Care and Use Committee (IACUC protocol 00001636, PI: Mazur).</p>
<p>To evaluate the effects of SETD2 ablation on the development and progression of lung adenocarcinoma, we utilized <italic>Kras<sup>cKI-G12C/+</sup></italic>, <italic>Trp53<sup>loxP/loxP</sup></italic> (<italic>K<sup>C</sup>P</italic>), and <italic>Kras<sup>cKI-G12C/+</sup></italic>, <italic>Trp53<sup>loxP/loxP</sup></italic>, <italic>Setd2<sup>loxP/loxP</sup></italic> (<italic>K<sup>C</sup>P;Setd2</italic>). To generate tumors in the lungs of <italic>K<sup>C</sup>P;Setd2</italic> and control <italic>K<sup>C</sup>P</italic> mutant mice we used replication-deficient adenoviruses expressing Cre-recombinase (Ad-Cre) as previously described (<xref ref-type="bibr" rid="c55">55</xref>). Briefly, 8-week-old mice were anesthetized by continuous gaseous infusion of 2% isoflurane for at least 10 min using a veterinary anesthesia system. Ad-Cre was delivered to the lungs by intratracheal lavage. Prior to administration, the virus was precipitated with calcium phosphate to improve the delivery of Cre by increasing the efficiency of viral infection of the lung epithelium. Mice were treated with one dose of 5 × 10<sup>6</sup> PFU of Ad-Cre. Mice were analyzed for tumor formation and progression at indicated timepoints after viral infection. The survival endpoint was determined by overall health criteria scoring. Mouse health status and weight were checked daily.</p>
</sec>
<sec id="s4f">
<title>Histology and immunohistochemistry</title>
<p>Tissue specimens were fixed in 4% buffered formalin for 24 hours and stored in 70% ethanol until paraffin embedding. 3-μm sections were stained with hematoxylin and eosin (HE) or used for immunostaining studies. The following antibodies were used (at the indicated dilutions): cleaved Caspase 3 (CST #9664, 1:200), Ki67 (BD Bioscience #550609, 1:1000), H3K36me3 (CST #4909, 1:1000). Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded tissue (FFPE) sections using a biotin-avidin HRP conjugate method (Vectastain ABC-HRP kit, #PK4000) as described before (<xref ref-type="bibr" rid="c56">56</xref>). Sections were developed with DAB and counterstained with hematoxylin. Pictures were taken using a PreciPoint M8 microscope equipped with the PointView software and quantified using Image J software (v1.53k, RRID:SCR_003070) and QuPath (v0.5.1, RRID:SCR_018257).</p>
</sec>
<sec id="s4g">
<title>Nucleosome pulldown assays</title>
<p>2.5 pmol of GST-SETD2 was added to nucleosome binding buffer (50 mM Tris-Cl pH 7.6, 300 mM NaCl, 0.1% NP-40, 0.5% bovine serum albumin, 10% glycerol) to a final volume of 25 µL. 12.5 pmol of biotinylated nucleosome was added and rotated overnight at 4° C. 1 µL of streptavidin Dynabeads (Fisher) were equilibrated in nucleosome binding buffer and resuspended to a final volume of 7.5 µL. Resuspended beads were then added to the nucleosome-enzyme mixture and rotated at 4° C for 1 hour. Beads were pelleted on a magnet, the supernatant (unbound) fraction was collected, and the beads were washed with 200 µL of nucleosome binding buffer three times. Following the final wash, beads were resuspended in 15 µL of a 1x SDS-PAGE loading dye and stored at 4° C until immunoblotting.</p>
</sec>
<sec id="s4h">
<title>Electromobility shift assay (EMSA)</title>
<p>Nucleosomes were incubated with recombinant SETD2<sub>SET</sub> in EMSA buffer (30 mM Tris-HCl pH 7.5, 100 mM KCl, 25 mM MgCl<sub>2</sub>, 6 mM DTT (Dithiothreitol), 0.0075% Tween 20, 12% Glycerol) for 15 min at room temperature and analyzed by native 0.2X TBE-PAGE. Each reaction contained 250 nM of nucleosome with increasing concentrations of domain (0, 1, 2, 3, 4, 5 µM). Gels were stained with Sybr Gold (Thermo #S11494).</p>
</sec>
<sec id="s4i">
<title>Quantification and statistical analysis</title>
<p>Please refer to the Figure legends or the Experimental Details for description of sample size (n) and statistical details. All values for n are for individual mice or individual samples. Sample sizes were chosen based on previous experience with given experiments. Differences were statistically analyzed by unpaired two-tailed t-test, and one-way ANOVA with Dunnet’s test for multiple comparisons as indicated.</p>
</sec>
</sec>
</body>
<back>
<sec id="s7" sec-type="data-availability">
<title>Data availability</title>
<p>Plasmids, antibodies, and cell lines generated in this study will be available from the lead contact upon request with a completed material transfer agreement.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>This work was supported in part by grants from the NIH to O.G. (R35 GM139569), O.G. and P.K.M. (R01 CA272844, R01 CA278940), P.K.M. (R01 CA236949, R01 CA266280, R01 CA272843). P.K.M. is also supported by DoD PRCRP Career Development Award (CA181486), CPRIT IIRA (RP220391) and CPRIT Scholar in Cancer Research (RR160078). R.M. is supported by a DARE fellowship. This work was also supported in part by grants from the NIH to B.D.S. (R35 GM126900) and J.M.D. (R35 GM152103). G.C.F. was supported by a predoctoral training grant from the National Institute for General Medical Sciences (T32 GM135128).</p>
</ack>
<sec id="d1e1615" sec-type="additional-information">
<title>Additional information</title>
<sec id="s5">
<title>Author Contributions</title>
<p>R.J.M. and N.M.F. contributed equally to this work. They were responsible for experimental design, execution, data analysis, and manuscript preparation for their sections of the work. G.C.F. contributed to analysis of histone acetylation on SETD2 activity and nucleosome binding under the supervision of J.M.D. and B.D.S. H.D. and M.C. helped R.J.M. perform NSD2 assays. S.H. and T.C. contributed to histopathological evaluation and IHC analysis. O.G. and P.K.M. were equally responsible for supervision of research, data interpretation and manuscript preparation.</p>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bhat</surname>, <given-names>K. P.</given-names></string-name>, <string-name><surname>Umit Kaniskan</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Jin</surname>, <given-names>J.</given-names></string-name>, and <string-name><surname>Gozani</surname>, <given-names>O.</given-names></string-name></person-group> (<year>2021</year>) <article-title>Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease</article-title> <source>Nat Rev Drug Discov</source> <pub-id pub-id-type="doi">10.1038/s41573-020-00108-x</pub-id></mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Ahn</surname>, <given-names>J. H.</given-names></string-name>, and <string-name><surname>Wang</surname>, <given-names>G. G.</given-names></string-name></person-group> (<year>2019</year>) <article-title>Understanding histone H3 lysine 36 methylation and its deregulation in disease</article-title> <source>Cell Mol Life Sci</source> <volume>76</volume>, <fpage>2899</fpage>–<lpage>2916</lpage> <pub-id pub-id-type="doi">10.1007/s00018-019-03144-y</pub-id></mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Husmann</surname>, <given-names>D.</given-names></string-name>, and <string-name><surname>Gozani</surname>, <given-names>O</given-names></string-name></person-group>. (<year>2019</year>) <article-title>Histone lysine methyltransferases in biology and disease</article-title> <source>Nat Struct Mol Biol</source> <volume>26</volume>, <fpage>880</fpage>–<lpage>889</lpage> <pub-id pub-id-type="doi">10.1038/s41594-019-0298-7</pub-id></mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bennett</surname>, <given-names>R. L.</given-names></string-name>, <string-name><surname>Swaroop</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Troche</surname>, <given-names>C.</given-names></string-name>, and <string-name><surname>Licht</surname>, <given-names>J. D</given-names></string-name></person-group>. (<year>2017</year>) <article-title>The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer</article-title> <source>Cold Spring Harb Perspect Med</source> <volume>7</volume>, <pub-id pub-id-type="doi">10.1101/cshperspect.a026708</pub-id></mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Edmunds</surname>, <given-names>J. W.</given-names></string-name>, <string-name><surname>Mahadevan</surname>, <given-names>L. C.</given-names></string-name>, and <string-name><surname>Clayton</surname>, <given-names>A. L</given-names></string-name></person-group>. (<year>2008</year>) <article-title>Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation</article-title> <source>EMBO J</source> <volume>27</volume>, <fpage>406</fpage>–<lpage>420</lpage> <pub-id pub-id-type="doi">10.1038/sj.emboj.7601967</pub-id></mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baubec</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Colombo</surname>, <given-names>D. F.</given-names></string-name>, <string-name><surname>Wirbelauer</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Schmidt</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Burger</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Krebs</surname>, <given-names>A. R.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2015</year>) <article-title>Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation</article-title> <source>Nature</source> <volume>520</volume>, <fpage>243</fpage>–<lpage>247</lpage> <pub-id pub-id-type="doi">10.1038/nature14176</pub-id></mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jha</surname>, <given-names>D. K.</given-names></string-name>, <string-name><surname>Pfister</surname>, <given-names>S. X.</given-names></string-name>, <string-name><surname>Humphrey</surname>, <given-names>T. C.</given-names></string-name>, and <string-name><surname>Strahl</surname>, <given-names>B. D</given-names></string-name></person-group>. (<year>2014</year>) <article-title>SET-ting the stage for DNA repair</article-title> <source>Nat Struct Mol Biol</source> <volume>21</volume>, <fpage>655</fpage>–<lpage>657</lpage> <pub-id pub-id-type="doi">10.1038/nsmb.2866</pub-id></mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Almeida</surname>, <given-names>S. F.</given-names></string-name>, <string-name><surname>Grosso</surname>, <given-names>A. R.</given-names></string-name>, <string-name><surname>Koch</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Fenouil</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Carvalho</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Andrade</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2011</year>) <article-title>Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36</article-title> <source>Nat Struct Mol Biol</source> <volume>18</volume>, <fpage>977</fpage>–<lpage>983</lpage> <pub-id pub-id-type="doi">10.1038/nsmb.2123</pub-id></mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Duns</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>van den Berg</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>van Duivenbode</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Osinga</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Hollema</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Hofstra</surname>, <given-names>R. M.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2010</year>) <article-title>Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma</article-title> <source>Cancer Res</source> <volume>70</volume>, <fpage>4287</fpage>–<lpage>4291</lpage> <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0120</pub-id></mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>He</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Zeng</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Ling</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2014</year>) <article-title>Identification of functional cooperative mutations of SETD2 in human acute leukemia</article-title> <source>Nature Genetics</source> <volume>46</volume>, <fpage>287</fpage>–<lpage>293</lpage> <pub-id pub-id-type="doi">10.1038/ng.2894</pub-id></mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wen</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Xi</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Jiang</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Stratton</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Peng</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2014</year>) <article-title>ZMYND11 links histone H3.3K36me3 to transcription elongation and tumour suppression</article-title> <source>Nature</source> <volume>508</volume>, <fpage>263</fpage>–<lpage>268</lpage> <pub-id pub-id-type="doi">10.1038/nature13045</pub-id></mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuo</surname>, <given-names>A. J.</given-names></string-name>, <string-name><surname>Cheung</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Zee</surname>, <given-names>B. M.</given-names></string-name>, <string-name><surname>Kioi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lauring</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2011</year>) <article-title>NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic Programming</article-title> <source>Mol Cell</source> <volume>44</volume>, <fpage>609</fpage>–<lpage>620</lpage> <pub-id pub-id-type="doi">10.1016/j.molcel.2011.08.042</pub-id></mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hudlebusch</surname>, <given-names>H. R.</given-names></string-name>, <string-name><surname>Santoni-Rugiu</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Simon</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Ralfkiaer</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Rossing</surname>, <given-names>H. H.</given-names></string-name>, <string-name><surname>Johansen</surname>, <given-names>J. V.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2011</year>) <article-title>The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors</article-title> <source>Clin Cancer Res</source> <volume>17</volume>, <fpage>2919</fpage>–<lpage>2933</lpage> <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1302</pub-id></mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jaffe</surname>, <given-names>J. D.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Chan</surname>, <given-names>H. M.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Huether</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Kryukov</surname>, <given-names>G. V.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia</article-title> <source>Nat Genet</source> <volume>45</volume>, <fpage>1386</fpage>–<lpage>1391</lpage> <pub-id pub-id-type="doi">10.1038/ng.2777</pub-id></mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aytes</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Giacobbe</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Mitrofanova</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Ruggero</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Cyrta</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Arriaga</surname>, <given-names>J.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>) <article-title>NSD2 is a conserved driver of metastatic prostate cancer progression</article-title> <source>Nat Commun</source> <volume>9</volume>, <fpage>5201</fpage> <pub-id pub-id-type="doi">10.1038/s41467-018-07511-4</pub-id></mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yuan</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Flores</surname>, <given-names>N. M.</given-names></string-name>, <string-name><surname>Hausmann</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Lofgren</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Kharchenko</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Angulo-Ibanez</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2021</year>) <article-title>Elevated NSD3 histone methylation activity drives squamous cell lung cancer</article-title> <source>Nature</source> <volume>590</volume>, <fpage>504</fpage>–<lpage>508</lpage> <pub-id pub-id-type="doi">10.1038/s41586-020-03170-y</pub-id></mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sengupta</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Zeng</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Hausmann</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ghosh</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Yuan</surname>, <given-names>G.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2021</year>) <article-title>NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis</article-title> <source>Mol Cell</source> <volume>81</volume>, <fpage>4481</fpage>–<lpage>4492.e4489</lpage> <pub-id pub-id-type="doi">10.1016/j.molcel.2021.08.034</pub-id></mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dalgliesh</surname>, <given-names>G. L.</given-names></string-name>, <string-name><surname>Furge</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Greenman</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Bignell</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Butler</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2010</year>) <article-title>Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes</article-title> <source>Nature</source> <volume>463</volume>, <fpage>360</fpage>–<lpage>363</lpage> <pub-id pub-id-type="doi">10.1038/nature08672</pub-id></mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Walton</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Lawson</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Prinos</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Finelli</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Arrowsmith</surname>, <given-names>C.</given-names></string-name>, and <string-name><surname>Ailles</surname>, <given-names>L</given-names></string-name></person-group>. (<year>2023</year>) <article-title>PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma</article-title> <source>Nat Rev Urol</source> <volume>20</volume>, <fpage>96</fpage>–<lpage>115</lpage> <pub-id pub-id-type="doi">10.1038/s41585-022-00659-1</pub-id></mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Foggetti</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Cai</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Hellyer</surname>, <given-names>J. A.</given-names></string-name>, <string-name><surname>Lin</surname>, <given-names>W. Y.</given-names></string-name>, <string-name><surname>Ayeni</surname>, <given-names>D.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2021</year>) <article-title>Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo</article-title> <source>Cancer Discov</source> <volume>11</volume>, <fpage>1736</fpage>–<lpage>1753</lpage> <pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-1385</pub-id></mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kadara</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Choi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Parra</surname>, <given-names>E. R.</given-names></string-name>, <string-name><surname>Rodriguez-Canales</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Gaffney</surname>, <given-names>S. G.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up</article-title> <source>Ann Oncol</source> <volume>28</volume>, <fpage>75</fpage>–<lpage>82</lpage> <pub-id pub-id-type="doi">10.1093/annonc/mdw436</pub-id></mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Walter</surname>, <given-names>D. M.</given-names></string-name>, <string-name><surname>Venancio</surname>, <given-names>O. S.</given-names></string-name>, <string-name><surname>Buza</surname>, <given-names>E. L.</given-names></string-name>, <string-name><surname>Tobias</surname>, <given-names>J. W.</given-names></string-name>, <string-name><surname>Deshpande</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Gudiel</surname>, <given-names>A. A.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma</article-title> <source>Cancer Res</source> <volume>77</volume>, <fpage>1719</fpage>–<lpage>1729</lpage> <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-2159</pub-id></mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mar</surname>, <given-names>B. G.</given-names></string-name>, <string-name><surname>Chu</surname>, <given-names>S. H.</given-names></string-name>, <string-name><surname>Kahn</surname>, <given-names>J. D.</given-names></string-name>, <string-name><surname>Krivtsov</surname>, <given-names>A. V.</given-names></string-name>, <string-name><surname>Koche</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Castellano</surname>, <given-names>C. A.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2017</year>) <article-title>SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia</article-title> <source>Blood</source> <volume>130</volume>, <fpage>2631</fpage>-<lpage>2641</lpage> <pub-id pub-id-type="doi">10.1182/blood-2017-03-775569</pub-id></mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cookis</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Lydecker</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Sauer</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Kasinath</surname>, <given-names>V.</given-names></string-name>, and <string-name><surname>Nogales</surname>, <given-names>E</given-names></string-name></person-group>. (<year>2025</year>) <article-title>Structural basis for the inhibition of PRC2 by active transcription histone posttranslational modifications</article-title> <source>Nat Struct Mol Biol</source> <volume>32</volume>, <fpage>393</fpage>–<lpage>404</lpage> <pub-id pub-id-type="doi">10.1038/s41594-024-01452-x</pub-id></mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yuan</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Huang</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>Zhu</surname>, <given-names>B.</given-names></string-name></person-group> (<year>2011</year>) <article-title>H3K36 methylation antagonizes PRC2-mediated H3K27 methylation</article-title> <source>J Biol Chem</source> <volume>286</volume>, <fpage>7983</fpage>–<lpage>7989</lpage> <pub-id pub-id-type="doi">10.1074/jbc.M110.194027</pub-id></mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmitges</surname>, <given-names>F. W.</given-names></string-name>, <string-name><surname>Prusty</surname>, <given-names>A. B.</given-names></string-name>, <string-name><surname>Faty</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Stutzer</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Lingaraju</surname>, <given-names>G. M.</given-names></string-name>, <string-name><surname>Aiwazian</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2011</year>) <article-title>Histone methylation by PRC2 is inhibited by active chromatin marks</article-title> <source>Mol Cell</source> <volume>42</volume>, <fpage>330</fpage>–<lpage>341</lpage> <pub-id pub-id-type="doi">10.1016/j.molcel.2011.03.025</pub-id></mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jani</surname>, <given-names>K. S.</given-names></string-name>, <string-name><surname>Jain</surname>, <given-names>S. U.</given-names></string-name>, <string-name><surname>Ge</surname>, <given-names>E. J.</given-names></string-name>, <string-name><surname>Diehl</surname>, <given-names>K. L.</given-names></string-name>, <string-name><surname>Lundgren</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Muller</surname>, <given-names>M. M.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Histone H3 tail binds a unique sensing pocket in EZH2 to activate the PRC2 methyltransferase</article-title> <source>Proc Natl Acad Sci U S A</source> <volume>116</volume>, <fpage>8295</fpage>–<lpage>8300</lpage> <pub-id pub-id-type="doi">10.1073/pnas.1819029116</pub-id></mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Finogenova</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Bonnet</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Poepsel</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Schafer</surname>, <given-names>I. B.</given-names></string-name>, <string-name><surname>Finkl</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Schmid</surname>, <given-names>K.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2020</year>) <article-title>Structural basis for PRC2 decoding of active histone methylation marks H3K36me2/3</article-title> <source>eLife</source> <volume>9</volume>:<elocation-id>e61964</elocation-id>, <pub-id pub-id-type="doi">10.7554/eLife.61964</pub-id></mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Hu</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Horth</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Bareke</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Rosenbaum</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Kwon</surname>, <given-names>S. Y.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2022</year>) <article-title>H3K36 dimethylation shapes the epigenetic interaction landscape by directing repressive chromatin modifications in embryonic stem cells</article-title> <source>Genome Res</source> <volume>32</volume>, <fpage>825</fpage>–<lpage>837</lpage> <pub-id pub-id-type="doi">10.1101/gr.276383.121</pub-id></mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnson</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Mercer</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Greenbaum</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Bronson</surname>, <given-names>R. T.</given-names></string-name>, <string-name><surname>Crowley</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Tuveson</surname>, <given-names>D. A.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2001</year>) <article-title>Somatic activation of the K-ras oncogene causes early onset lung cancer in mice</article-title> <source>Nature</source> <volume>410</volume>, <fpage>1111</fpage>–<lpage>1116</lpage> <pub-id pub-id-type="doi">10.1038/35074129</pub-id></mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jackson</surname>, <given-names>E. L.</given-names></string-name>, <string-name><surname>Willis</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Mercer</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Bronson</surname>, <given-names>R. T.</given-names></string-name>, <string-name><surname>Crowley</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Montoya</surname>, <given-names>R.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2001</year>) <article-title>Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras</article-title> <source>Genes Dev</source> <volume>15</volume>, <fpage>3243</fpage>–<lpage>3248</lpage> <pub-id pub-id-type="doi">10.1101/gad.943001</pub-id></mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rogers</surname>, <given-names>Z. N.</given-names></string-name>, <string-name><surname>McFarland</surname>, <given-names>C. D.</given-names></string-name>, <string-name><surname>Winters</surname>, <given-names>I. P.</given-names></string-name>, <string-name><surname>Seoane</surname>, <given-names>J. A.</given-names></string-name>, <string-name><surname>Brady</surname>, <given-names>J. J.</given-names></string-name>, <string-name><surname>Yoon</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice</article-title> <source>Nat Genet</source> <volume>50</volume>, <fpage>483</fpage>–<lpage>486</lpage> <pub-id pub-id-type="doi">10.1038/s41588-018-0083-2</pub-id></mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xie</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Sahin</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Wakamatsu</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Inoue-Yamauchi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Han</surname>, <given-names>S.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2023</year>) <article-title>SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis</article-title> <source>JCI Insight</source> <volume>8</volume>, <pub-id pub-id-type="doi">10.1172/jci.insight.154120</pub-id></mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Campbell</surname>, <given-names>J. D.</given-names></string-name>, <string-name><surname>Alexandrov</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Wala</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Berger</surname>, <given-names>A. H.</given-names></string-name>, <string-name><surname>Pedamallu</surname>, <given-names>C. S.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas</article-title> <source>Nat Genet</source> <volume>48</volume>, <fpage>607</fpage>–<lpage>616</lpage> <pub-id pub-id-type="doi">10.1038/ng.3564</pub-id></mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wiesweg</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kasper</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Worm</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Herold</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Reis</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Sara</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer</article-title> <source>Oncogene</source> <volume>38</volume>, <fpage>2953</fpage>–<lpage>2966</lpage> <pub-id pub-id-type="doi">10.1038/s41388-018-0634-0</pub-id></mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Francis</surname>, <given-names>J. W.</given-names></string-name>, <string-name><surname>Hausmann</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ikram</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Yin</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Mealey-Farr</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Flores</surname>, <given-names>N. M.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2024</year>) <article-title>FAM86A methylation of eEF2 links mRNA translation elongation to tumorigenesis</article-title> <source>Mol Cell</source> <volume>84</volume>, <fpage>1753</fpage>-<lpage>1763.e1757</lpage> <pub-id pub-id-type="doi">10.1016/j.molcel.2024.02.037</pub-id></mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Trojer</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>C. F.</given-names></string-name>, <string-name><surname>Cheung</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Kuo</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Drury</surname>, <given-names>W. J.</given-names>, <suffix>3rd</suffix></string-name>, <etal>et al.</etal></person-group> (<year>2009</year>) <article-title>The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate</article-title> <source>J Biol Chem</source> <volume>284</volume>, <fpage>34283</fpage>–<lpage>34295</lpage> <pub-id pub-id-type="doi">10.1074/jbc.M109.034462</pub-id></mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seeliger</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Soeroes</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Klingberg</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Schwarzer</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Grubmuller</surname>, <given-names>H.</given-names></string-name>, and <string-name><surname>Fischle</surname>, <given-names>W</given-names></string-name></person-group>. (<year>2012</year>) <article-title>Quantitative assessment of protein interaction with methyl-lysine analogues by hybrid computational and experimental approaches</article-title> <source>ACS Chem Biol</source> <volume>7</volume>, <fpage>150</fpage>–<lpage>154</lpage> <pub-id pub-id-type="doi">10.1021/cb200363r</pub-id></mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nitsch</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Zorro Shahidian</surname>, <given-names>L.</given-names></string-name>, and <string-name><surname>Schneider</surname>, <given-names>R.</given-names></string-name></person-group> (<year>2021</year>) <article-title>Histone acylations and chromatin dynamics: concepts, challenges, and links to metabolism</article-title> <source>EMBO Rep</source> <volume>22</volume>, <fpage>e52774</fpage> <pub-id pub-id-type="doi">10.15252/embr.202152774</pub-id></mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghoneim</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Fuchs</surname>, <given-names>H. A.</given-names></string-name>, and <string-name><surname>Musselman</surname>, <given-names>C. A</given-names></string-name></person-group>. (<year>2021</year>) <article-title>Histone Tail Conformations: A Fuzzy Affair with DNA</article-title> <source>Trends Biochem Sci</source> <volume>46</volume>, <fpage>564</fpage>–<lpage>578</lpage> <pub-id pub-id-type="doi">10.1016/j.tibs.2020.12.012</pub-id></mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jain</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Marunde</surname>, <given-names>M. R.</given-names></string-name>, <string-name><surname>Burg</surname>, <given-names>J. M.</given-names></string-name>, <string-name><surname>Gloor</surname>, <given-names>S. L.</given-names></string-name>, <string-name><surname>Joseph</surname>, <given-names>F. M.</given-names></string-name>, <string-name><surname>Poncha</surname>, <given-names>K. F.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2023</year>) <article-title>An acetylation-mediated chromatin switch governs H3K4 methylation read-write capability</article-title> <source>eLife</source> <volume>12</volume>, <pub-id pub-id-type="doi">10.7554/eLife.82596</pub-id></mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marunde</surname>, <given-names>M. R.</given-names></string-name>, <string-name><surname>Fuchs</surname>, <given-names>H. A.</given-names></string-name>, <string-name><surname>Burg</surname>, <given-names>J. M.</given-names></string-name>, <string-name><surname>Popova</surname>, <given-names>I. K.</given-names></string-name>, <string-name><surname>Vaidya</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hall</surname>, <given-names>N. W.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2024</year>) <article-title>Nucleosome conformation dictates the histone code</article-title> <source>eLife</source> <volume>13</volume>, <pub-id pub-id-type="doi">10.7554/eLife.78866</pub-id></mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fox</surname>, <given-names>G. C.</given-names></string-name>, <string-name><surname>Poncha</surname>, <given-names>K. F.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>B. R.</given-names></string-name>, <string-name><surname>van der Maas</surname>, <given-names>L. N.</given-names></string-name>, <string-name><surname>Robbins</surname>, <given-names>N. N.</given-names></string-name>, <string-name><surname>Graham</surname>, <given-names>B.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2024</year>) <article-title>Histone H3K18 &amp; H3K23 acetylation directs establishment of MLL-mediated H3K4 methylation</article-title> <source>J Biol Chem</source> <volume>300</volume>, <fpage>107527</fpage> <pub-id pub-id-type="doi">10.1016/j.jbc.2024.107527</pub-id></mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Tian</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Yuan</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Deng</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Sengupta</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Cheng</surname>, <given-names>Z.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2021</year>) <article-title>Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases</article-title> <source>Nature</source> <volume>590</volume>, <fpage>498</fpage>–<lpage>503</lpage> <pub-id pub-id-type="doi">10.1038/s41586-020-03069-8</pub-id></mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Napoles</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Mermoud</surname>, <given-names>J. E.</given-names></string-name>, <string-name><surname>Wakao</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Tang</surname>, <given-names>Y. A.</given-names></string-name>, <string-name><surname>Endoh</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Appanah</surname>, <given-names>R.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2004</year>) <article-title>Polycomb group proteins Ring1A/B link ubiquitylation of histone H2A to heritable gene silencing and X inactivation</article-title> <source>Dev Cell</source> <volume>7</volume>, <fpage>663</fpage>–<lpage>676</lpage> <pub-id pub-id-type="doi">10.1016/j.devcel.2004.10.005</pub-id></mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bilokapic</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>Halic</surname>, <given-names>M.</given-names></string-name></person-group> (<year>2019</year>) <article-title>Nucleosome and ubiquitin position Set2 to methylate H3K36</article-title> <source>Nat Commun</source> <volume>10</volume>, <fpage>3795</fpage> <pub-id pub-id-type="doi">10.1038/s41467-019-11726-4</pub-id></mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luscan</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Laurendeau</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Malan</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Francannet</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Odent</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Giuliano</surname>, <given-names>F.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2014</year>) <article-title>Mutations in SETD2 cause a novel overgrowth condition</article-title> <source>J Med Genet</source> <volume>51</volume>, <fpage>512</fpage>–<lpage>517</lpage> <pub-id pub-id-type="doi">10.1136/jmedgenet-2014-102402</pub-id></mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lawrence</surname>, <given-names>M. S.</given-names></string-name>, <string-name><surname>Stojanov</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Mermel</surname>, <given-names>C. H.</given-names></string-name>, <string-name><surname>Robinson</surname>, <given-names>J. T.</given-names></string-name>, <string-name><surname>Garraway</surname>, <given-names>L. A.</given-names></string-name>, <string-name><surname>Golub</surname>, <given-names>T. R.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2014</year>) <article-title>Discovery and saturation analysis of cancer genes across 21 tumour types</article-title> <source>Nature</source> <volume>505</volume>, <fpage>495</fpage>–<lpage>501</lpage> <pub-id pub-id-type="doi">10.1038/nature12912</pub-id></mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Xue</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Cao</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Bai</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Mu</surname>, <given-names>Z.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2021</year>) <article-title>Cryo-EM structure of SETD2/Set2 methyltransferase bound to a nucleosome containing oncohistone mutations</article-title> <source>Cell Discov</source> <volume>7</volume>, <fpage>32</fpage> <pub-id pub-id-type="doi">10.1038/s41421-021-00261-6</pub-id></mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Markert</surname>, <given-names>J. W.</given-names></string-name>, <string-name><surname>Soffers</surname>, <given-names>J. H.</given-names></string-name>, and <string-name><surname>Farnung</surname>, <given-names>L</given-names></string-name></person-group>. (<year>2025</year>) <article-title>Structural basis of H3K36 trimethylation by SETD2 during chromatin transcription</article-title> <source>Science</source> <volume>387</volume>, <fpage>528</fpage>–<lpage>533</lpage> <pub-id pub-id-type="doi">10.1126/science.adn6319</pub-id></mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hacker</surname>, <given-names>K. E.</given-names></string-name>, <string-name><surname>Fahey</surname>, <given-names>C. C.</given-names></string-name>, <string-name><surname>Shinsky</surname>, <given-names>S. A.</given-names></string-name>, <string-name><surname>Chiang</surname>, <given-names>Y. J.</given-names></string-name>, <string-name><surname>DiFiore</surname>, <given-names>J. V.</given-names></string-name>, <string-name><surname>Jha</surname>, <given-names>D. K.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation</article-title> <source>J Biol Chem</source> <volume>291</volume>, <fpage>21283</fpage>–<lpage>21295</lpage> <pub-id pub-id-type="doi">10.1074/jbc.M116.739375</pub-id></mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Hausmann</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Lyu</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>T. M.</given-names></string-name>, <string-name><surname>Lofgren</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Flores</surname>, <given-names>N. M.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2020</year>) <article-title>SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy</article-title> <source>Cancer Cell</source> <volume>37</volume>, <fpage>834</fpage>–<lpage>849.e813</lpage> <pub-id pub-id-type="doi">10.1016/j.ccell.2020.04.014</pub-id></mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jonkers</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Meuwissen</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>van der Gulden</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Peterse</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>van der Valk</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Berns</surname>, <given-names>A</given-names></string-name></person-group>. (<year>2001</year>) <article-title>Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer</article-title> <source>Nat Genet</source> <volume>29</volume>, <fpage>418</fpage>–<lpage>425</lpage> <pub-id pub-id-type="doi">10.1038/ng747</pub-id></mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raymond</surname>, <given-names>C. S.</given-names></string-name>, and <string-name><surname>Soriano</surname>, <given-names>P.</given-names></string-name></person-group> (<year>2007</year>) <article-title>High-efficiency FLP and PhiC31 site-specific recombination in mammalian cells</article-title> <source>PloS one</source> <volume>2</volume>, <fpage>e162</fpage> <pub-id pub-id-type="doi">10.1371/journal.pone.0000162</pub-id></mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Hausmann</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Carlson</surname>, <given-names>S. M.</given-names></string-name>, <string-name><surname>Fuentes</surname>, <given-names>M. E.</given-names></string-name>, <string-name><surname>Francis</surname>, <given-names>J. W.</given-names></string-name>, <string-name><surname>Pillai</surname>, <given-names>R.</given-names></string-name> <etal>et al.</etal></person-group> (<year>2019</year>) <article-title>METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis</article-title> <source>Cell</source> <volume>176</volume>, <fpage>491</fpage>–<lpage>504.e421</lpage> <pub-id pub-id-type="doi">10.1016/j.cell.2018.11.038</pub-id></mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Szkop</surname>, <given-names>K. J.</given-names></string-name>, <string-name><surname>Jeong</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Jovanovic</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Husmann</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2024</year>) <article-title>SMYD5 methylation of rpL40 links ribosomal output to gastric cancer</article-title> <source>Nature</source> <pub-id pub-id-type="doi">10.1038/s41586-024-07718-0</pub-id></mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107451.2.sa3</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Shi</surname>
<given-names>Xiaobing</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Van Andel Institute</institution>
</institution-wrap>
<city>Grand Rapids</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Convincing</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Fundamental</kwd>
</kwd-group>
</front-stub>
<body>
<p>This is a <bold>fundamental</bold> study providing molecular insight into how cross-talk between histone modifications regulates the histone H3K36 methyltransferase SETD2. The manuscript contains excellent quality data, and the conclusions are <bold>convincing</bold> and justified. This work will be of interest to many biochemists working in the field of chromatin biology and epigenetics.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107451.2.sa2</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>In this manuscript, Mack and colleagues investigate the role of posttranslational modifications, including lysine acetylation and ubiquitination, in methyltransferase activity of SETD2 and show that this enzyme functions as a tumor suppressor in a KRASG12C-driven lung adenocarcinoma. In contrast to H3K36me2-specific oncogenic methyltransferases, the deletion of SETD2, which is capable of H3K36 trimethylation, increases lethality in a KRASG12C-driven lung adenocarcinoma mouse tumor model. In vitro, the authors demonstrate that polyacetylation of histone H3, particularly of H3K27, H3K14 and H3K23, promotes the catalytic activity of SETD2, whereas ubiquitination of H2A and H2B has no effect.</p>
<p>Strengths:</p>
<p>Overall, this is a well-designed study that addresses an important biological question regarding the functioning of the essential chromatin component. The manuscript contains excellent quality data, and the conclusions are convincing and justified. This work will be of interest to many biochemists working in the field of chromatin biology and epigenetics.</p>
<p>Comments on revisions:</p>
<p>All previous comments are well addressed, and I enthusiastically support publication.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107451.2.sa1</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>Human histone H3K36 methyltransferase Setd2 has been previously shown to be a tumor suppressor in lung and pancreatic cancer. In this manuscript by Mack et al., the authors first use a mouse KRASG12D-driven lung cancer model to confirm in vivo that Setd2 depletion exacerbates tumorigenesis. They then investigate the enzymatic regulation of the Setd2 SET domain in vitro, demonstrating that H2A, H3, or H4 acetylation stimulates Setd2-SET activity, with specific enhancement by mono-acetylation at H3K14ac or H3K27ac. In contrast, histone ubiquitination has no effect. The authors propose that H3K27ac may regulate Setd2-SET activity by facilitating its binding to nucleosomes. This work provides insight into how cross-talk between histone modifications regulates Setd2 function.</p>
<p>Comments on revisions:</p>
<p>(1) Regarding New Figure 2F lane 1, please reference PMID: 33972509 Fig 4D bottom. Setd2-SET is a well-known robust K36 trimethylase. Why, under the authors' conditions, do WT nucleosomes show a significant amount of K36me1 and K36me2 accumulation, whereas K36me3 is not as pronounced? As a comparison, the authors should also report the evidence for the efficiency of each chemical modification that generates K36 methylation mimic.</p>
<p>(2) The bottom panel of Figure 2B does not match the top one; the number of repeats should be indicated in the figure legends.</p>
<p>(3) In Figure 4E, the differences between Setd2-bound WT and acetylated nucleosomes are minimal, as judged by both the decreasing trend of unbound nucleosomes and the increasing trend of bound fractions. This experiment needs to be quantified based on multiple repeats.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107451.2.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mack</surname>
<given-names>Ricardo J</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1078-9888</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Flores</surname>
<given-names>Natasha M</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fox</surname>
<given-names>Geoffrey C</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5898-0847</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Dong</surname>
<given-names>Hanyang</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cebeci</surname>
<given-names>Metehan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hausmann</surname>
<given-names>Simone</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chasan</surname>
<given-names>Tourkian</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dowen</surname>
<given-names>Jill M</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Strahl</surname>
<given-names>Brian D</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4947-6259</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Mazur</surname>
<given-names>Pawel K</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5820-8344</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Gozani</surname>
<given-names>Or</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1365-4463</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1 (Public review):</bold></p>
<p>(1) Labels should be added in the Figures and should be uniform across all Figures (some are distorted).</p>
</disp-quote>
<p>We thank the Reviewer for pointing out this issue. As requested, labels have been edited to ensure they are legible and are consistent in font, size, and style.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Public review):</bold></p>
<p>(1) As for Figure 2F, Setd2-SET activity on WT rNuc (H3) appears to be significantly lower compared to what is extensively reported in the literature. This is particularly puzzling given that Figure 2B suggests that using 3H-SAM, H3-nuc are much better substrates than K36me1, whereas in Figure 3F, rH3 is weaker than K36me1. It is recommended for the authors to perform additional experimental repeats and include a quantitative analysis to ensure the consistency and reliability of these findings.</p>
</disp-quote>
<p>We appreciate the Reviewer’s points. We respectfully suggest that these comments may reflect potential confusion around interpreting how different assays detect in vitro methylation, what data can and cannot be compared, and the nature of the different substrates used.</p>
<p>With respect to point 1 (Western signal significantly lower compared to extensive literature): To the best of our knowledge, it would be extremely challenging to make a quantitative argument comparing the strength of the Western signal in Figure 2F with results reported in the literature. Specifically, comparing our results with previous studies would require (1) all the studies to have used the exact same antibodies as antibody signal intensities vary depending on the specific activity and selectively of a particular antibody and even its lot number, (2) similar in vitro methylation reaction condition, (3) the same type of recombinant nucleosomes used, and so on. Further, given that these are Western blots, we do not understand how one could interpret an absolute activity level. In the figure, all we can conclude is that in in vitro methylation reactions, our recombinant SETD2 protein methylates rNucs to generate mono-, di-, and tri-methylation at K36 (using vetted antibodies (see Fig. 2e)). If there is a specific paper within the extensive literature that the Reviewer highlights, we could look more into the details of why the signals are different (our guess is that any difference would largely be due to the use of different antibodies). We add that it might be challenging to find a similar experiment performed in the literature; we are not aware of a similar experiment.</p>
<p>With respect to comparing Figure 2B and 2F: We do not understand how one can meaningfully compare incorporation of radiolabeled SAM to antibody-based detection on film using an antibody against specific methyl states. In particular, regarding the question regarding comparing rH3 vs H3K36me1 nucleosomes, we point out that in using recombinant nucleosomes installed with native modifications (e.g. H3K36me1), in which the entire population of the starting material is mono-methylated, then naturally the Western signal with an anti-H3K36me1 antibody will be strong. In Fig. 2b, the assay is incorporation of radiolabeled methyl, which is added to the preexiting mono-methylated substrate. In other words, the results are entirely consistent if one understands how the methylation reactions were performed, how methylation was detected, and the nature of the reagents.</p>
<disp-quote content-type="editor-comment">
<p>(2) The additional bands observed in Figure 4B, which appear to be H4, should be accompanied by quantification of the intensity of the H3 bands to better assess K36me3 activity. Additionally, the quantification presented in Figure 4C for SAH does not seem accurate as it potentially includes non-specific methylation activity, likely from H4. This needs to be addressed for clarity and accuracy.</p>
</disp-quote>
<p>We thank the reviewer for this comment. The additional bands observed in Figure 4B represent degradation products of histone H3, not H4 methylation. This is commonly seen in in vitro reactions using recombinant nucleosomes, where partial proteolysis of H3 can occur under the assay conditions.</p>
<disp-quote content-type="editor-comment">
<p>(3) In Figure 4E, the differences between bound and unbound substrates are not sufficiently pronounced. Given the modest differences observed, authors might want to consider repeating the assay with sufficient replicates to ensure the results are statistically robust.</p>
</disp-quote>
<p>In Figure 4E, we observe a clear difference between the bound and unbound substrate. To aid interpretation, we have clarified in the figure where the bound complex migrates on the gel, while the unbound nucleosomes migrate at the bottom of the gel. The differences are indeed subtle, which we highlight in the text.</p>
<disp-quote content-type="editor-comment">
<p>(4) Regarding labeling, there are multiple issues that need correction: In the depiction of Epicypher's dNuc, it is crucial to clearly mark H2B as the upper band, rather than ambiguously labeling H2A/H2B together when two distinct bands are evident. In Figure 3B and D, the histones appear to be mislabeled, and the band corresponding to H4 has been cut off. It would be beneficial to refer to Figure 3E for correct labeling to maintain consistency and accuracy across figures.</p>
</disp-quote>
<p>Thank you for pointing this out. To avoid any confusion, we have delineated the H2B and H2A markers and indicate the band corresponding to H4.</p>
<disp-quote content-type="editor-comment">
<p>(5) There are issues with the image quality in some blots; for instance, Figure 2EF and Figure 2D exhibit excessive contrast and pixelation, respectively. These issues could potentially obscure or misrepresent the data, and thus, adjustments in image processing are recommended to provide clearer, more accurate representations.</p>
</disp-quote>
<p>Contrast adjustments were applied uniformly across each entire image and were not used to modify any specific region of the blot. We have corrected the issue of increased pixelation in Figure 2D.</p>
<disp-quote content-type="editor-comment">
<p>(6) The authors are recommended to provide detailed descriptions of the materials used, including catalog numbers and specific products, to allow for reproducibility and verification of experimental conditions.</p>
</disp-quote>
<p>We have added the missing product specifications and catalog numbers to ensure clarity and reproducibility of the experiments.</p>
<disp-quote content-type="editor-comment">
<p>(7) The identification of Setd2 as a tumor suppressor in KrasG12C-driven LUAD is a significant finding. However, the discussion on how this discovery could inspire future therapeutic approaches needs to be more balanced. The current discussion (Page 10) around the potential use of inhibitors is somewhat confusing and could benefit from a clearer explanation of how Setd2's role could be targeted therapeutically. It would be beneficial for the authors to explore both current and potential future strategies in a more structured manner, perhaps by delineating between direct inhibitors, pathway modulators, and other therapeutic modalities.</p>
</disp-quote>
<p>SETD2 is a tumor suppressor in lung cancer (as we show here and many others have clearly established in the literature) and thus we would recommend avoiding a SETD2 inhibitor to treat solid tumors, as it could have a very much unwanted affect.  Our discussion addresses a different point regarding the relative importance of the enzymatic activity versus other, nonenzymatic functions of SETD2. We believe that a detailed exploration of the therapeutic potential of inhibiting SETD2 would be better suited in a review or a more therapy-focused manuscript.</p>
</body>
</sub-article>
</article>